EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517899-38-00

Acronym

EORTC-2361-GUCG

Enrollment

Registered

2025-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)

Brief summary

Objective Response, defined as Complete Response (CR) or Partial Response (PR) based on RECIST 1.1 criteria, on conventional imaging.

Detailed description

Safety in all treated patients using Common Terminology Criteria for Adverse Events (CTCAE) V5.0, DCR at 6 months, PFS, Time to start of next systemic treatment, OS

Interventions

DRUGPluvicto 1 000 MBq/mL solution for injection/infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response, defined as Complete Response (CR) or Partial Response (PR) based on RECIST 1.1 criteria, on conventional imaging.	—

Secondary

Measure	Time frame
Safety in all treated patients using Common Terminology Criteria for Adverse Events (CTCAE) V5.0, DCR at 6 months, PFS, Time to start of next systemic treatment, OS	—

Countries

Belgium, France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026